Concepedia

Author

Irmina Diala

Puma Biotechnology (United States)

Also Known As

I Diala, I. Diala, Irmina Diala

85

Publications

820

Citations

11

H-Index

25

Concepts

All Affiliations

Puma Biotechnology (United States)The University of Texas MD Anderson Cancer CenterVirginia Commonwealth University
ID

About

Irmina Diala is an author at Puma Biotechnology (United States) specializing in medicine, cancer research, and cancer cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

108

2

Cell Biology

2

2

93

3

Engineering

1

1

15

4

Diagnostic Sciences

1

1

15

5

Pathology

1

1

15

Irmina Diala

×

12

Publications

770

Citations

11

H-Index

YearCitations

HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers

Bob T. Li, Flavia Michelini, Sandra Misale,

Cancer Discovery

2020

274

Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis

Aadya Nagpal, Richard P. Redvers, Xiawei Ling,

Breast Cancer Research

2019

148

Telomere protection and TRF2 expression are enhanced by the canonical Wnt signalling pathway

Irmina Diala, Nicole Wagner, Frédérique Magdinier,

EMBO Reports

2013

80

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

Neil T. Conlon, Jeffrey J. Kooijman, Suzanne J.C. van Gerwen,

British Journal of Cancer

2021

68

Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer

Ming Zhao, Stephen M. Scott, Kurt W. Evans,

Clinical Cancer Research

2021

58

Use of <i>Ex</i>   <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung Cancer

Elena V. Ivanova, Mari Kuraguchi, Man Xu,

Clinical Cancer Research

2020

40

Neratinib augments the lethality of [regorafenib + sildenafil]

Laurence Booth, Jane L. Roberts, Rumeesa Rais,

Journal of Cellular Physiology

2018

33

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Jangsoon Lee, Huey Liu, Troy Pearson,

Biomedicines

2021

18

Screening for Oral Cancer Using Electrochemical Telomerase Assay

Mana Hayakawa, Shinobu Sato, Irmina Diala,

Electroanalysis

2015

15

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition

Laurence Booth, Jane L. Roberts, Rumeesa Rais,

Cancer Biology & Therapy

2018

13

Page 1